On the 12th, they signed the agreement and are taking a commemorative photo. From the left, Jin-tae Kim, CEO of U2Bio, and Jun-kyung Ji, CEO of Polaris AI. Provided by Polaris AI.
Polaris AI announced on the 13th that it has signed a Memorandum of Understanding (MOU) to expand cooperation in the public and private healthcare markets with U2Bio, a customized healthcare specialist company.
U2Bio is a healthcare platform company that combines information technology (IT) and biotechnology (BT). Through its platform 'Lab2Gene,' it introduced the industry's first real-time EMR (Electronic Medical Record) linked in vitro diagnostic testing service and has accumulated expertise in the medical and medical data fields by collaborating with over 2,500 medical institutions nationwide.
Through this MOU, Polaris AI plans to combine its existing system construction experience and artificial intelligence (AI) technology with the medical IT possessed by U2Bio to jointly research and commercialize medical data automation and analysis solutions, and to introduce AI-based vertical services.
Additionally, Polaris AI intends to combine U2Bio's microbiome and genetic analysis technologies with its personalized analysis algorithms to provide scientifically data-driven, customized AI healthcare services, thereby strengthening competitiveness in the future AI-based digital healthcare market.
Ji Jun-kyung, CEO of Polaris AI, stated, "We expect to provide digital healthcare vertical AI services together with U2Bio using Polaris AI's system construction solutions and AI technology," and added, "Based on the cooperation between the two companies, we will introduce innovative services in the digital healthcare market."
Meanwhile, Polaris AI, having recently joined the Polaris Office Group, is pursuing growth by exploring vertical AI that applies AI across industries together with Polaris Office, which collaborates with various AI companies such as LG AI Research and Saltlux.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
